̽»¨¾«Ñ¡

Benedict Chambers grupp

The main focus of our research is to investigate the role of natural killer (NK) cells in the development of adaptive immune responses. The research focuses along two lines. (1) The interaction between dendritic cells (DC) and NK cells. (2) How NK cells can affect T and B cell mediated responses by direct physical interaction.

The Benedict Chambers team is part of the Hans-Gustaf Ljunggren research group at the Center for Infectious Medicine (CIM).

About our research

The main focus of our research is to investigate the role of natural killer (NK) cells in the development of adaptive immune responses. The research focuses along two lines. (1) The interaction between dendritic cells (DC) and NK cells. (2) How NK cells can affect T and B cell mediated responses by direct physical interaction.

In particular, we are looking at the role of TRAIL in the elimination of DC in vivo and the role of 2B4 (CD244) on NK cells in the stimulation of T cells. How NK cells interact with DC or cells of the adaptive immune system has implications for the generation of a successful immune response aimed at eradication of infections or tumors. The studies also have relevance for the uncontrolled immune reactions occurring during autoimmune reactions and during allergic responses.

Keywords

NK cell, T cell, cellular, cytotoxicity, cancer, virus, toxoplasma

Projects

Phosphatidylserine and "turning off" of cytotoxic lymphocytes

One of the problems with trying to develop immune responses to tumors is that the tumors are often "tolerized" by the immune system. As mentioned previously, this may be due in part to DC producing TGFβ upon interaction with phosphatidylserine (PS) on apoptotic cells. However, many studies have found that increased numbers TGFβ expressing lymphocytes in tumors are correlated with poor prognosis. For NK cells, TGFβ can reduce the expression of NKG2D on the NK cell surface, cytokine production and cytotoxicity. CD8+ T cells are similarly affected by TGFβ. However, it is unclear whether the T cells and NK cells which also express PS receptors can make TGFβ directly upon interaction with PS on apoptotic tumor cells. Thus this study continues to investigate what role PS plays in inducing tumor "tolerance" in NK cells and T cells.

Immuno-evasion by infectious pathogens

While studying NK cell interactions with dendritic cells, we have found novel techniques of immuno-evasion by the parasite Toxoplasma gondii. In contrast to previous studies where viral and bacterial infected dendritic cells are protected from NK cell mediated lysis, Toxoplasma gondii infected dendritic become more sensitive to NK cells, allowing the parasite to exit the dendritic cell and infect surrounding NK cells. One effect of NK cells infection by Toxoplasma gondii, is that they no longer are cytotoxic and no longer produce IFNγ and other proinflammatory cytokines, essential in the defence against Toxoplasma gondii. Future plans will examine how Toxoplasma gondii can control the production of inflammatory cytokines in NK cells and identify target molecules by gene array. These studies may identify new molecules that could be used to treat inflammatory responses.

NK cell recruitment and activation by dendritic cells in vivo

We have demonstrated that plasmacytoid dendritic cells either generated in culture with flt3L or purified from spleens stimulated with the CpG can induce NK cell migration to the peritoneal cavity and the activation of NK cells as measured by cytotoxicity and IFNγ production. However in the course of these studies, it was noticed that the different dendritic cell subsets appeared to induce NK cell migration using different chemokines and differential levels of activation. We are now investigating the relative role of the CD8+ and CD8- dendritic cells in the activation of NK cells.

Open positions

We always want to get in touch with talented potential co-workers. If you are interested in doing research within our group, as a degree project or as a researcher, please contact the group leader: benedict.chambers@ki.se

Publikationer

Utvalda publikationer

  • Article: FRONTIERS IN IMMUNOLOGY. 2018;9:505
    Vashist N; Trittel S; Ebensen T; Chambers BJ; Guzman CA; Riese P
  • Article: PLOS PATHOGENS. 2017;13(12):e1006739
    Kanatani S; Fuks JM; Olafsson EB; Westermark L; Chambers B; Varas-Godoy M; Uhlen P; Barragan A
  • Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2012;75(1):54-60
    Dominguez-Villar M; Garcia-Cozar FJ; Chambers BJ
  • Article: INFECTION AND IMMUNITY. 2011;79(8):3046-3052
    Dellacasa-Lindberg I; Fuks JM; Arrighi RBG; Lambert H; Wallin RPA; Chambers BJ; Barragan A
  • Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2010;40(8):2155-2164
    Persson CM; Chambers BJ
  • Article: JOURNAL OF LEUKOCYTE BIOLOGY. 2009;86(1):91-101
    Seth S; Georgoudaki A-M; Chambers BJ; Qiu Q; Kremmer E; Maier MK; Czeloth N; Ravens I; Foerster R; Bernhardt G
  • Article: INFECTION AND IMMUNITY. 2009;77(3):970-976
    Persson CM; Lambert H; Vutova PP; Dellacasa-Lindberg I; Nederby J; Yagita H; Ljunggren H-G; Grandien A; Barragan A; Chambers BJ
  • Article: JOURNAL OF LEUKOCYTE BIOLOGY. 2008;83(1):56-63
    Wagner CS; Walther-Jallow L; Buentke E; Ljunggren H-G; Achour A; Chambers BJ
  • Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2008;67(1):30-36
    Persson CM; Assarsson E; Vahlne G; Brodin P; Chambers BJ
  • Article: CANCER RESEARCH. 2007;67(18):8450-8455
    Chambers B; Grufman P; Fredriksson V; Andersson K; Roseboom M; Laban S; Camps M; Wolpert EZ; Wiertz EJHJ; Offringa R; Ljunggren H-G; van Hall T
  • Article: JOURNAL OF IMMUNOLOGY. 2004;173(1):174-180
    Assarsson E; Kambayashi T; Schatzle JD; Cramer SO; von Bonin A; Jensen PE; Ljunggren HG; Chambers BJ
  • Article: JOURNAL OF IMMUNOLOGY. 2004;172(1):123-129
    Hayakawa Y; Screpanti V; Yagita H; Grandien A; Ljunggren HG; Smyth MJ; Chambers BJ
Nyckelord:
Immunologi inom det medicinska området Mikrobiologi inom det medicinska området
BC
±õ²Ô²Ô±ð³óÃ¥±ô±ô²õ²µ°ù²¹²Ô²õ°ì²¹°ù±ð:
Karin Vikström
2024-03-22